An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis

Trial Identifier: EFC18325
Sponsor: Sanofi
Collaborator:
Teva Branded Pharmaceutical Products R&D LLC
Start Date: October 2025
Primary Completion Date: May 2028
Study Completion Date: May 2028
Condition: Ulcerative Colitis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, Florida Coral Springs, Florida, United States, 33065
United States, Florida Kissimmee, Florida, United States, 34741
United States, Florida Miami, Florida, United States, 33186
United States, Florida Miami, Florida, United States, 33125
United States, Florida Miami, Florida, United States, 33126
United States, Florida Miami, Florida, United States, 33155
United States, Louisiana Monroe, Louisiana, United States, 71291
United States, Missouri Liberty, Missouri, United States, 64068
United States, New York Maspeth, New York, United States, 11378
United States, North Carolina Fayetteville, North Carolina, United States, 28304
United States, South Carolina West Columbia, South Carolina, United States, 29169
United States, Texas Harlingen, Texas, United States, 78550
United States, Texas Tyler, Texas, United States, 75701